1. Field of the Invention
The present invention relates generally to medical apparatus and methods for treatment. More particularly, the present invention relates to expandable prosthesis and methods for treating abdominal and other aneurysms.
Aneurysms are enlargements or “bulges” in blood vessels which are often prone to rupture and which therefore present a serious risk to the patient. Aneurysms may occur in any blood vessel but are of particular concern when they occur in the cerebral vasculature or the patient's aorta.
The present invention is particularly concerned with aneurysms occurring in the aorta, particularly those referred to as aortic aneurysms. Abdominal aortic aneurysms (AAA's) are classified based on their location within the aorta as well as their shape and complexity. Aneurysms which are found below the renal arteries are referred to as infrarenal abdominal aortic aneurysms. Suprarenal abdominal aortic aneurysms occur above the renal arteries, while thoracic aortic aneurysms (TAA's) occur in the ascending, transverse, or descending part of the upper aorta.
Infrarenal aneurysms are the most common, representing about seventy percent (70%) of all aortic aneurysms. Suprarenal aneurysms are less common, representing about 20% of the aortic aneurysms. Thoracic aortic aneurysms are the least common and often the most difficult to treat. Most or all present endovascular systems are also too large (above 12 F) for percutaneous introduction.
The most common form of aneurysm is “fusiform,” where the enlargement extends about the entire aortic circumference. Less commonly, the aneurysms may be characterized by a bulge on one side of the blood vessel attached at a narrow neck. Thoracic aortic aneurysms are often dissecting aneurysms caused by hemorrhagic separation in the aortic wall, usually within the medial layer. The most common treatment for each of these types and forms of aneurysm is open surgical repair. Open surgical repair is quite successful in patients who are otherwise reasonably healthy and free from significant co-morbidities. Such open surgical procedures are problematic, however, since access to the abdominal and thoracic aortas is difficult to obtain and because the aorta must be clamped off, placing significant strain on the patient's heart.
Over the past decade, endoluminal grafts have come into widespread use for the treatment of aortic aneurysm in patients who cannot undergo open surgical procedures. In general, endoluminal repairs access the aneurysm “endoluminally” through either or both iliac arteries in the groin. The grafts, which typically have been fabric or membrane tubes supported and attached by various stent structures, are then implanted, typically requiring several pieces or modules to be assembled in situ. Successful endoluminal procedures have a much shorter recovery period than open surgical procedures.
Present endoluminal aortic aneurysm repairs, however, suffer from a number of limitations. A significant number of endoluminal repair patients experience leakage at the proximal juncture (attachment point closest to the heart) within two years of the initial repair procedure. While such leaks can often be fixed by further endoluminal procedures, the need to have such follow-up treatments significantly increases cost and is certainly undesirable for the patient. A less common but more serious problem has been graft migration. In instances where the graft migrates or slips from its intended position, open surgical repair is required. This is a particular problem since the patients receiving the endoluminal grafts are often those who are not considered good candidates for open surgery. Further shortcomings of the present endoluminal graft systems relate to both deployment and configuration. The multiple component systems require additional time for introducing each piece and even more time for assembling the pieces in situ. Such techniques are not only more time consuming, they are also more technically challenging, increasing the risk of failure. Current devices are also unsuitable for treating many geometrically complex aneurysms, particularly infrarenal aneurysms with little space between the renal arteries and the upper end of the aneurysm, referred to as short-neck or no-neck aneurysms. Aneurysms having torturous geometries, are also difficult to treat.
A particularly promising endoluminal graft is described in U.S. Publication No. 2006/0025853, which corresponds to parent application U.S. application Ser. No. 11/187,471, the full disclosure of which has previously been incorporated herein by reference. That patent application describes the treatment of the aortic and other aneurysms with a double-walled structure which is filled with a hardenable material which has cured in situ. The structure conforms to the shape of the aneurysmal space and resists migration and endoleaks. The particular design described, however, has certain shortcomings. For example, the lumen provided by the inner wall of the filled structure can sometimes deform so that the shape of the lumen is less than ideal. In other rare instances, leakage paths on the aortic or iliac ends of the graft may form.
For these reasons, it would desirable to provide improved methods, systems, and prosthesis for the endoluminal treatment of aortic aneurysms. Such improved methods, systems, and treatments should preferably provide implanted prosthesis which result in minimal or no endoleaks, resist migration, are relatively easy to deploy, have a low introduction profile (preferably below 12 F), and can treat most or all aneurismal configurations, including short-neck and no-neck aneurysms as well as those with highly irregular and asymmetric geometries. Further it would be desirable to provide fillable aneurysmal grafts having supported inner blood flow lumens and improved blood flow transitions at the aortic and/or iliac ends. At least some of these objectives will be met by the inventions described hereinafter.
2. Description of the Background Art
Grafts and endografts having fillable components are described in U.S. Pat. Nos. 4,641,653; 5,530,528; 5,665,117; and 5,769,882; U.S. Patent Publications 2004/0016997; and PCT Publications WO 00/51522 and WO 01/66038. The following patents and published applications describe stents and grafts having cuffs, extenders, liners, and related structures: U.S. Pat. Nos. 6,918,926; 6,843,803; 6,663,667; 6,656,214; 6,592,614; 6,409,757; 6,334,869; 6,283,991; 6,193,745; 6,110,198; 5,994,750; 5,876,448; 5,824,037; 5,769,882; 5,693,088; and 4,728,328; and U.S. Published Application Nos. 2005/0028484; 2005/0065592; 2004/0082989; 2004/0044358; 2003/0216802; 2003/0204249; 2003/0204242; 2003/0135269; 2003/0130725; and 2002/0052643.
The present invention provides methods and systems for the endoluminal treatment of aneurysms, particularly aortic aneurysms including both abdominal aortic aneurysms (AAA's) and thoracic aortic aneurysms (TAA's). The systems include prostheses which comprise double-walled filling structures which are pre-shaped and otherwise adapted to substantially fill the enlarged volume of an aneurysm, particularly a fusiform aneurysm, leaving a lumen in place for blood flow.
The double-walled filling structures will thus usually have a generally toroidal structure with an outer wall, an inner wall, a potential space or volume between the outer and inner walls to be filled with a filling medium, and a generally tubular lumen inside of the inner wall which provides the blood flow lumen after the prosthesis has been deployed. The shape of the filling structure will be preferably adapted to conform to the aneurysm being treated. In some instances, the filling structure can be shaped for the aneurismal geometry of a particular patient using imaging and computer-aided design and fabrication techniques. In other instances, a family or collection of filling structures will be developed having different geometries and sizes so that a treating physician may select a specific filling structure to treat a particular patient based on the size and geometry of that patient's aneurysm. In all instances, the outer wall of the filling structure will conform or be conformable to the inner surface of the aneurysm being treated. While the inner wall of the structure will be aligned with lumens of the blood vessels on either side of the prosthesis after the prosthesis has been deployed.
The filling structures of the prosthesis will usually be formed from a non-compliant material, such as parylene, polyester (e.g., Dacron®), PET, PTFE, and/or a compliant material, such as silicone, polyurethane, latex, or combinations thereof. Usually, it will be preferred to form at least the outer wall partially or entirely from a non-compliant material to enhance conformance of the outer wall to the inner surface of the aneurysm. This is particularly true when the aneurysm has been individually designed and/or sized for the patient being treated.
The walls of the filling structures may consist of a single layer or may comprise multiple layers which are laminated, glued, heat bonded, ultrasonically bonded, or otherwise formed together. Different layers may comprise different materials, including both compliant and/or non-compliant materials. The structure walls may also be reinforced in various ways, including braid reinforcement layers, filament reinforcement layers, and the like.
In addition to the filling structures just described, the aneurysm treatment systems of the present invention will further include at least a first scaffold separate from the filling structure, where the scaffold can be expanded within the generally tubular lumen which provides the blood flow after the filling structure has been deployed in the aneurysm. The first scaffold will be adapted to expand within at least a first portion of the tubular lumen of the filling structure and may provide one or more specific advantages. For example, the scaffold may support and smooth the inside wall of the tubular lumen which in some cases might otherwise become uneven during hardening of the polymer fill. Scaffolds may also provide for anchoring of the filling structure, particularly at the aortic end of the graft when placed in an AAA. The scaffold may be partly or wholly covered with a membrane in order to form a graft. In such cases, the graft structure may help provide a transition from the blood vessel into the generally tubular lumen of the filling structure from the aortic end. Alternatively, the graft structure could provide one or a pair of transitions out of the iliac end of the filling structure. In a particular example, a graft structure can be used on either side of the filling structure in order to treat additional or continuing aneurysmal regions in the adjacent blood vessel.
The scaffolds used in combination with the double-walled filling structures of the present invention may take any form generally associated with a vascular or other luminal stents or grafts. For example, the scaffolds may be formed from an elastic material, particularly a spring steel or shape memory alloy, so that they may be delivered in a constrained configuration and allowed to expand in situ to anchor within the generally tubular lumen of the filling structure. Alternatively, the scaffold may be formed from a malleable metal or other material, such as stainless steel, and be delivered using a balloon catheter or other conventional stent expansion device. Grafts will usually comprise a metal frame covered in part or in whole by a membrane material, such as polyester, PTFE, or the like.
The geometry of the scaffold may also vary considerably. Often, the scaffold will extend over substantially the entire length of the inner wall of the generally tubular lumen of the filling structure. Frequently, the scaffold will extend outwardly from at least one of the ends of the generally tubular lumen into the adjacent blood vessel. The scaffold may also extend outwardly from both ends of the generally tubular lumen as well as covering the entire inner wall surface of that lumen.
In other instances, multiple scaffold structures may be provided within a single generally tubular lumen of the filling structure. In such cases, the two or more scaffolds may be adapted to be placed in series, frequently overlapping. In other instances, scaffolds may be adapted to be spaced apart at either or both ends and optionally at regions between the ends. In the case of covered scaffolds, the scaffold will typically comprise a metal frame, at least a portion of which is covered by a polymeric membrane or other covering. In other instances, however, the scaffold or portions thereof may be polymeric and optionally formed from a biodegradable polyester. It will frequently be desirable to cover the outside of the scaffold over at least those portions of the scaffold which engage the inner wall of the generally tubular lumen of the filling structure. The scaffolds and/or their covers may be coated with, impregnated with, or otherwise coupled to drugs or other bioactive substances for a variety of purposes, such as promoting tissue ingrowth, reducing thrombosis, reducing the risk of invention, and the like.
Preferred delivery protocols for the filling structures will utilize delivery catheters having a balloon or other expandable support for carrying the filling structure. When using balloons, the balloons will preferably be substantially or entirely non-compliant, although compliant and combination compliant/non-compliant balloons may also find use. The balloon or other mechanical expansion components of the delivery catheter will initially be disposed within the inner tubular lumen of the filling structure, with the filling structure generally being collapsed into a low width or low profile configuration over the expansion element. The delivery catheter may then be introduced intraluminally, typically into the iliac artery and upwardly to the region within the aorta to be treated. The delivery catheter will also include one or more lumens, tubes, or other components or structures for delivering the filling medium in a fluid form to an internal filling cavity of the filling structure. Thus, the delivery catheter can be used to both initially place and locate the filling structure of the prosthesis at the aneurismal site. Once at the aneurismal site, the internal tubular lumen of the structure can be expanded using the balloon or other expandable element on the delivery catheter. The filling structure itself will be filled and expanded by delivering the filling medium via the catheter into the internal volume of the filling structure. Both expansion and filling operations may be performed simultaneously, or can be performed in either order, i.e. the filling structure may be filled first with the delivery catheter balloon being expanded second, or vice versa. The filling structure(s) and/or delivery balloons may have radiopaque markers to facilitate placement and/or pressure sensors for monitoring filling and inflation pressures during deployment.
In preferred aspects of the present invention, the filling structure will be filled with a fluid (prior to hardening as described herein below) at a pressure which is lower than that of the expansion force provided by the delivery catheter, typically the filling pressure of the expandable balloon. Typically, the filling structure will be filled with filling medium at a pressure from 80 mm of Hg to 1000 mm of Hg, preferably from 200 mm of Hg to 600 mm of Hg, while the delivery balloon is inflated to a pressure in the range from 100 mm of Hg to 5000 mm of Hg, preferably from 400 mm of Hg to 1000 mm of Hg. These pressures are gage pressures, i.e. measured relative to atmospheric pressure.
As described thus far, in the present invention includes delivery of a single prosthesis and filling structure to an aneurysm. Delivery of a single filling structure will be particularly suitable for aneurysms which are remote from a vessel bifurcation so that both ends of the filling structure are in communication with only a single blood vessel lumen. In the case of aneurysms located adjacent a vessel bifurcation, such as the most common, infrarenal abdominal aortic aneurysms, it will often be preferable to utilize two such filling structures introduced in a generally adjacent, parallel fashion within the aneurismal volume. In the specific case of the infrarenal aneurysms, each prosthesis will usually be delivered separately, one through each of the two iliac arteries. After locating the filling structures of the prosthesis within the aneurismal space, they can be filled simultaneously or sequentially to fill and occupy the entire aneurismal volume, leaving a pair of blood flow lumens.
Suitable filling materials will be fluid initially to permit delivery through the delivery catheter and will be curable or otherwise hardenable so that, once in place, the filling structure can be given a final shape which will remain after the delivery catheter is removed. The fillable materials will usually be curable polymers which, after curing, will have a fixed shape with a shore hardness typically in the range from 10 durometer to 140 durometer. The polymers may be delivered as liquids, gels, foams, slurries, or the like. In some instances, the polymers may be epoxies or other curable two-part systems. In other instances, the polymer may comprise a single material which, when exposed to the vascular environment within the filling structure, changes state over time, typically from zero to ten minutes.
In a preferred aspect of the present invention, after curing, the filling material will have a specific gravity, typically in the range from 0.1 to 5, more typically from 0.8 to 1.2 which is generally the same as blood or thrombus. The filling material may also include bulking and other agents to modify density, viscosity, mechanical characteristics or the like, including microspheres, fibers, powders, gasses, radiopaque materials, drugs, and the like. Exemplary filling materials include polyurethanes, collagen, polyethylene glycols, microspheres, and the like.
The filling structures may be modified in a variety of other ways within the scope of the present invention. For example, the external surfaces of the filling structures may be partially or entirely modified to enhance placement within the aneurismal space, typically by promoting tissue ingrowth or mechanically interlocking with the inner surface of the aneurysm. Such surface modifications include surface roughening, surface stippling, surface flocking, fibers disposed over the surface, foam layers disposed over the surface, rings, and the like. It is also possible to provide biologically active substances over all or a portion of the external surface of the filling structure, such as thrombogenic substances, tissue growth promotants, biological adhesives, and the like. It would further be possible to provide synthetic adhesives, such as polyacrylamides, over the surface to enhance adherence.
In some instances, it will be desirable to modify all or a portion of the internal surface of the filling structure. Such surface modifications may comprise surface roughening, rings, stipples, flocking, foam layers, fibers, adhesives, and the like. The purpose of such surface modification will usually be to enhance the filling and bonding to the filling material, and to control the minimum wall thickness when the structure is filled particularly after the filling material has been cured. In particular instances, locations of the filling structure may be pressed together when the structure is deployed, thus potentially excluding filling material. In such instances, it will be desirable if the surfaces of the filling structure can adhere directly to each other.
In view of the above general descriptions of the present invention, the following specific embodiments may be better understood. In a first specific embodiment, methods for treating an aneurysm comprise positioning at least one double-walled filling structure across the aneurysm. By “across” the aneurysms, it is meant generally that the filling structure will extend axially from one anatomical location which has been identified by imaging or otherwise as the beginning of the aneurysm to a space-part location (or locations in the case of bifurcated aneurysm) where it has been established that the aneurysm ends. After positioning, the at least one filling structure is filled with a fluid filling medium so that an outer wall of the structure conforms to the inside of the aneurysm and an inner wall of the structure forms a generally tubular lumen to provide for blood flow after the filling structure has been deployed. While the filling structure is being filled, after the filling structure has been filled, or during both periods, the tubular lumen will preferably be supported, typically by a balloon or mechanically expansible element. After the filling structure has been filled, the filling material or medium is hardened while the tubular lumen remains supported. Supporting the tubular lumen during hardening assures that the lumen will have a desired geometry, will properly align with adjacent vascular lumens and that the tubular lumen being formed remains aligned with the native aortic and/or iliac artery lumens after the prosthesis has been fully implanted. Preferably, the support will be provided by a balloon which extends proximally and distally of the filling structure where the balloon may slightly “overexpand” in order to assure the desired smooth transition and conformance of the tubular lumen provided by the filling structure with the native vessel lumens.
After hardening, the support will be removed, leaving the filling structure in place. In some instances, however, prior to hardening, it will be desirable to confirm proper placement of the filling structure. This can be done using imaging techniques or otherwise testing for patency and continuity. In some instances, it may be desirable to first fill the filling structure with saline or other non-hardenable substance to make sure that the geometry of the filling structure is appropriate for the patient being treated. After testing, the saline may be removed and replaced with the hardenable filler.
In a second specific embodiment of the present invention, abdominal aortic aneurysms and other bifurcated aneurysms are treated by positioning first and second double-walled filling structures within the aneurismal volume. The first and second double-walled filling structures are positioned across the aneurysm, as defined above, extending from the aorta beneath the renal arteries to each of the iliac arteries, respectively. The first fluid filling structure is filled with a fluid filling material, the second filling structure is also filled with a fluid material, and the outer walls of each filling structure will conform to the inside surface of the aneurysm as well as to each other, thus providing a pair of tubular lumens for blood flow from the aorta to each of the iliac arteries. Preferably, the tubular lumens of each of the first and second filling structures are supported while they are being filled or after they have been filled. Further, the tubular lumens will preferably remain supported while the filling material is hardened, thus assuring that the transitions to the tubular lumens to the native vessel lumens remain properly aligned and conformed.
In a third specific embodiment of the present invention, systems for treating aneurysms comprise at least one double-walled filling structure and at least one delivery catheter having an expandable support positionable within a tubular lumen of the filling structure. The systems will usually further comprise a suitable hardenable or curable fluid filling medium. The particular characteristics of the filling structure and delivery balloon have been described above in connection with the methods of the present invention.
In a still further specific embodiment of the present invention, a system for treating abdominal aortic aneurysms comprises a first double-walled filling structure and a second double-walled filling structure. The first and second filling structures are adapted to be filled with a hardenable filling medium while they lie adjacent to each other within the aneurysm. The systems further comprise first and second delivery catheters which can be utilized for aligning each of the first and second filling structures properly with the right and left iliacs and the infrarenal aorta as they are being deployed, filled, and hardened.
The systems of the present invention for treating abdominal aortic aneurysms and other bifurcated lumens will typically include at least a first and a second scaffold, one for each of the tubular lumens defined by the first and second double-walled filling structures, respectively. The scaffolds will generally be the same as those described for the single filling structure embodiments, except that in some instances portions of the scaffold which extend into the adjacent blood vessel may be modified in order to enhance their ability to conform to each other. For example, the ends of the scaffolds may be modified to have D-shaped cross-sections so that when they are expanded, the flat surfaces of the D-shaped sections will engage each other to provide for a very full coverage of the area of the blood vessel. In other instances, the ends of the scaffolds which extend into the blood vessel may be formed into C-shaped structures which are expanded together to form a single generally continuous ring structure engaging the blood vessel wall.
A system 10 constructed in accordance with the principles of the present invention for delivering a double-walled filling structure 12 to an aneurysm includes the filling structure and a delivery catheter 14 having an expandable element 16, typically an inflatable balloon, at its distal end. The catheter 14 will comprise a guidewire lumen 18, a balloon inflation lumen (not illustrated) or other structure for expanding other expandable components, and a filling tube 20 for delivering a filling medium or material to an internal space 22 of the double-walled filling structure 12. The internal space 22 is defined between an outer wall 24 and inner wall 26 of the filling structure. Upon inflation with the filling material or medium, the outer wall will expand radially outwardly, as shown in broken line, as will the inner wall 26, also shown in broken line. Expansion of the inner wall 26 defines an internal lumen 28. The expandable balloon or other structure 16 will be expandable to support an inner surface of the lumen 28, as also in broken line in
Referring now to
The inner surface 30 of the filling volume 22 may also be modified by providing features, coatings, surface roughening, or a variety of other modifications. The purpose of such internal features is typically to enhance adherence of the walls to the filling material or medium as the medium is cured or otherwise hardened. In some instances, materials may be coated on all or a portion of the inside surface 30 to induce or catalyze hardening of the filling material as it is being introduced.
The double-walled filling structure 12 will typically comprise at least one valve 40 to permit the introduction of the filling material or medium into the internal volume 22. As illustrated, the valve 40 may be a simple flap valve. Other more complex ball valves, and other one-way valve structures may be provided. In other instances, two-way valve structures may be provided to permit both filling and selective emptying of the internal volume 22. In other instances, the filling tube may comprise a needle or other filling structure to pass through the valve 40 to permit both filling and removal of filling medium.
As illustrated in
Referring now to
Referring to
After the double-walled filling structure 12 is properly positioned, a hardenable inflation medium is introduced into the internal space 22 filling of the inner space 22 expands the outer wall 24 of the structure outwardly so that it conforms to the inner surface (S) of the aneurismal space.
Before, during, or after filling of the double-walled filling structure 12 with inflation medium, as illustrated in
After the filling material has been introduced to the filling structure 12, typically through the filling tube 20, the fluid filling material must be cured or otherwise hardened to provide for the permanent implant having a generally fixed structure which will remain in place in the particular aneurismal geometry. Methods for curing or hardening the filling material will depend on the nature of the filling material. For example, certain polymers may be cured by the application of energy, such as heat energy or ultraviolet light. Other polymers may be cured when exposed to body temperature, oxygen, or other conditions which cause polymerization of the fluid filling material. Still others may be mixed immediately prior to use and simply cure after a fixed time, typically minutes.
In accordance with the present invention, at least one scaffold will be placed into the tubular lumen defined by the inner wall 26. As illustrated in
As shown in
As shown in
As shown in
As shown in
The stents, grafts, and other scaffold structures will often be delivered using separate delivery catheters (not shown) of the type commonly used to intravascularly deliver stents and grafts. The scaffold delivery catheters may comprise balloons or other expansion elements for expanding malleable scaffolds in situ. Alternatively, the delivery catheters could comprise tubular sheaths for covering and constraining self-expanding scaffolds prior to release within the tubular lumens of the filling structures. Systems could also deliver the scaffold(s) simultaneously with the filling structure(s), often on a common delivery catheter system.
In a particular and preferred aspect of the present invention, a pair of double-walled filling structures will be used to treat infrarenal abdominal aortic aneurysms, instead of only a single filling structure as illustrated in
In treating an infrarenal abdominal aortic aneurysm using the pair of filling structures 112 and 212 illustrated in
After filling the filling structures 112 and 212 as illustrated in
As with the single filling structure embodiments described previously, the double filling structure embodiments will include at least one separate scaffold deployed within each of the tubular blood flow lumens. The scaffolds will generally be stent-like or graft-like vascular structures and will be deployed within the tubular lumens using balloon or other expansion catheters (in the case of malleable or balloon-expandable scaffolds) or using constraining sheaths (in the case of self-expanding scaffolds).
Referring in particular to
Referring now to
Referring now to
As shown in
Various modifications of the protocols described above will be within the scope of the present invention. For example, while the scaffolds have been shown as being delivered after deployment of the filling structure(s), it will also be possible to deliver the scaffolds simultaneously with or prior to deployment of the filling structures. For example, the scaffolds could be delivered on the same delivery catheter(s) used to deliver and/or shape the filling structures. The scaffolds could then be expanded at the same time as filling the filling structure or even prior to filling the filling structure.
While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
The present application is a continuation of U.S. Ser. No. 13/285,897 filed Oct. 31, 2011 (now U.S. Pat. No. 8,870,941), which is a Divisional of U.S. Ser. No. 11/413,460 filed Apr. 28, 2006 (now U.S. Pat. No. 8,048,145); which application is a continuation-in-part of U.S. Ser. No. 11/187,471 filed on Jul. 22, 2005 (now U.S. Pat. No. 7,530,988); which claimed the benefit of priority to Provisional Appln. No. 60/589,850 filed Jul. 22, 2004, the full disclosures of which are incorporated herein by reference. The present application also claims the benefit of priority to Provisional Appln. No. 60/675,158, filed on Apr. 28, 2005 and Appln. No. 60/736,602 filed Nov. 14, 2005. The full disclosures, all of which are incorporated herein by reference in their entirety, for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
4183102 | Guiset | Jan 1980 | A |
4565738 | Purdy | Jan 1986 | A |
4638803 | Rand | Jan 1987 | A |
4641653 | Rockey | Feb 1987 | A |
4704126 | Baswell | Nov 1987 | A |
4710192 | Liotta | Dec 1987 | A |
4728328 | Hughes et al. | Mar 1988 | A |
4731073 | Robinson | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4743258 | Ikada | May 1988 | A |
4763654 | Jang | Aug 1988 | A |
4856516 | Hillstead | Aug 1989 | A |
4858264 | Reinhart | Aug 1989 | A |
4892544 | Frisch | Jan 1990 | A |
4936057 | Rhoades | Jun 1990 | A |
4976692 | Atad | Dec 1990 | A |
5002532 | Gaiser | Mar 1991 | A |
5074845 | Miraki | Dec 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5133732 | Wiktor | Jul 1992 | A |
5139480 | Hickle | Aug 1992 | A |
5156620 | Pigott | Oct 1992 | A |
5195984 | Schatz | Mar 1993 | A |
5199226 | Rose | Apr 1993 | A |
5217484 | Marks | Jun 1993 | A |
5222970 | Reeves | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5242399 | Lau | Sep 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5263964 | Purdy | Nov 1993 | A |
5292331 | Houki et al. | Mar 1994 | A |
5314444 | Gianturco | May 1994 | A |
5316023 | Palmaz et al. | May 1994 | A |
5330528 | Lazim | Jul 1994 | A |
5334024 | Niznick | Aug 1994 | A |
5334217 | Das | Aug 1994 | A |
5350397 | Palermo | Sep 1994 | A |
5352199 | Tower | Oct 1994 | A |
5375612 | Cottenceau | Dec 1994 | A |
5383892 | Cardon | Jan 1995 | A |
5421955 | Lau | Jun 1995 | A |
5423849 | Engelson | Jun 1995 | A |
5425739 | Jessen | Jun 1995 | A |
5425744 | Fagan | Jun 1995 | A |
5441510 | Simpson | Aug 1995 | A |
5441515 | Khosravi | Aug 1995 | A |
5443477 | Marin | Aug 1995 | A |
5443496 | Schwartz | Aug 1995 | A |
5449373 | Pinchasik | Sep 1995 | A |
5485667 | Kleshinski | Jan 1996 | A |
5494029 | Lane | Feb 1996 | A |
5496277 | Terrnin | Mar 1996 | A |
5507767 | Maeda | Apr 1996 | A |
5507769 | Marin et al. | Apr 1996 | A |
5507771 | Gianturco | Apr 1996 | A |
5514115 | Frantzen | May 1996 | A |
5514154 | Lau | May 1996 | A |
5522882 | Gaterud | Jun 1996 | A |
5530528 | Houki et al. | Jun 1996 | A |
5531741 | Barbacci | Jul 1996 | A |
5534024 | Rogers et al. | Jul 1996 | A |
5545210 | Hess | Aug 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5554181 | Das | Sep 1996 | A |
5562641 | Flomenblit | Oct 1996 | A |
5562698 | Parker | Oct 1996 | A |
5562728 | Lazarus | Oct 1996 | A |
5569295 | Lam | Oct 1996 | A |
5578074 | Mirigian | Nov 1996 | A |
5578149 | De Scheerder | Nov 1996 | A |
5591195 | Taheri | Jan 1997 | A |
5591223 | Lock | Jan 1997 | A |
5591226 | Trerotola | Jan 1997 | A |
5591228 | Edoga | Jan 1997 | A |
5591230 | Horn | Jan 1997 | A |
5593417 | Rhodes | Jan 1997 | A |
5601600 | Ton | Feb 1997 | A |
5603721 | Lau | Feb 1997 | A |
5605530 | Fischell | Feb 1997 | A |
5607442 | Fischell | Mar 1997 | A |
5607445 | Summers | Mar 1997 | A |
5607468 | Rogers | Mar 1997 | A |
5609605 | Marshall | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5618299 | Khosravi | Apr 1997 | A |
5624411 | Tuch | Apr 1997 | A |
5630840 | Mayer | May 1997 | A |
5632760 | Sheiban | May 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632771 | Boatman | May 1997 | A |
D380266 | Boatman | Jun 1997 | S |
5634941 | Winston | Jun 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
D380831 | Kavteladze | Jul 1997 | S |
5662614 | Edoga | Sep 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5674241 | Bley | Oct 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683449 | Marcade | Nov 1997 | A |
5690643 | WiJay | Nov 1997 | A |
5693038 | Suzuki et al. | Dec 1997 | A |
5693067 | Purdy | Dec 1997 | A |
5693088 | Lazarus | Dec 1997 | A |
5697971 | Fischell | Dec 1997 | A |
5709707 | Lock | Jan 1998 | A |
5718713 | Frantzen | Feb 1998 | A |
5723004 | Dereume | Mar 1998 | A |
5725568 | Hastings | Mar 1998 | A |
5725572 | Lam | Mar 1998 | A |
5728068 | Leone | Mar 1998 | A |
5728131 | Frantzen | Mar 1998 | A |
5728158 | Lau | Mar 1998 | A |
5733303 | Israel et al. | Mar 1998 | A |
5735892 | Myers | Apr 1998 | A |
5735893 | Lau | Apr 1998 | A |
5741327 | Frantzen | Apr 1998 | A |
5741333 | Frid | Apr 1998 | A |
5746691 | Frantzen | May 1998 | A |
5755769 | Richard | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5766238 | Lau | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5776114 | Frantzen | Jul 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5782907 | Frantzen | Jul 1998 | A |
5785679 | Abolfathi et al. | Jul 1998 | A |
5788626 | Thompson | Aug 1998 | A |
5797953 | Tekulve | Aug 1998 | A |
5800393 | Sahota | Sep 1998 | A |
5800512 | Lentz et al. | Sep 1998 | A |
5800514 | Nunez | Sep 1998 | A |
5800525 | Bachinski | Sep 1998 | A |
5807404 | Richter | Sep 1998 | A |
5810872 | Kanesaka | Sep 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824037 | Fogarty et al. | Oct 1998 | A |
5824040 | Cox | Oct 1998 | A |
5824049 | Ragheb | Oct 1998 | A |
5824054 | Khosravi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5827321 | Roubin | Oct 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5843160 | Rhodes | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5846246 | Dirks | Dec 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5849037 | Frid | Dec 1998 | A |
5860998 | Robinson | Jan 1999 | A |
5863627 | Szycher | Jan 1999 | A |
5867762 | Rafferty et al. | Feb 1999 | A |
5868685 | Powell et al. | Feb 1999 | A |
5868708 | Hart | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5871537 | Holman | Feb 1999 | A |
5873907 | Frantzen | Feb 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5879381 | Moriuchi | Mar 1999 | A |
5888660 | Landoni et al. | Mar 1999 | A |
5902332 | Schatz | May 1999 | A |
5919224 | Thompson | Jul 1999 | A |
5928279 | Shannon et al. | Jul 1999 | A |
5931866 | Frantzen | Aug 1999 | A |
5944750 | Tanner | Aug 1999 | A |
5947991 | Cowan | Sep 1999 | A |
5948184 | Frantzen | Sep 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5984955 | Wisselink | Nov 1999 | A |
5994750 | Yagi | Nov 1999 | A |
6007573 | Wallace | Dec 1999 | A |
6015431 | Thornton | Jan 2000 | A |
6022359 | Frantzen | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6056776 | Lau | May 2000 | A |
6066167 | Lau | May 2000 | A |
6066168 | Lau | May 2000 | A |
6083259 | Frantzen | Jul 2000 | A |
6093199 | Brown | Jul 2000 | A |
6099548 | Taheri | Aug 2000 | A |
6110198 | Fogarty et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6123722 | Fogarty | Sep 2000 | A |
6124523 | Banas et al. | Sep 2000 | A |
6132457 | Chobotov | Oct 2000 | A |
6152144 | Lesh | Nov 2000 | A |
6152943 | Sawhney | Nov 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6187033 | Schmitt | Feb 2001 | B1 |
6187034 | Frantzen | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6190406 | Duerig et al. | Feb 2001 | B1 |
6193745 | Fogarty et al. | Feb 2001 | B1 |
6196230 | Hall et al. | Mar 2001 | B1 |
6203732 | Clubb | Mar 2001 | B1 |
6214022 | Taylor et al. | Apr 2001 | B1 |
6231562 | Khosravi et al. | May 2001 | B1 |
6235050 | Quiachon et al. | May 2001 | B1 |
6241761 | Villafana | Jun 2001 | B1 |
6254633 | Pinchuk et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6280466 | Kugler | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6290722 | Wang | Sep 2001 | B1 |
6290731 | Solovay et al. | Sep 2001 | B1 |
6293960 | Ken | Sep 2001 | B1 |
6296603 | Turnlund et al. | Oct 2001 | B1 |
6299597 | Buscemi et al. | Oct 2001 | B1 |
6299604 | Ragheb | Oct 2001 | B1 |
6312462 | McDermott et al. | Nov 2001 | B1 |
6312463 | Rourke et al. | Nov 2001 | B1 |
6325816 | Fulton, III | Dec 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6325823 | Horzewski | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6331191 | Chobotov | Dec 2001 | B1 |
6334869 | Leonhardt et al. | Jan 2002 | B1 |
6344056 | Dehdashtian | Feb 2002 | B1 |
6375675 | Dehdashtian et al. | Apr 2002 | B2 |
6395019 | Chobotov | May 2002 | B2 |
6409757 | Trout, III et al. | Jun 2002 | B1 |
6432131 | Ravenscroft | Aug 2002 | B1 |
6451047 | McCrea | Sep 2002 | B2 |
6463317 | Kucharczyk et al. | Oct 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6527799 | Shanley | Mar 2003 | B2 |
6544276 | Azizi | Apr 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6554858 | Dereume et al. | Apr 2003 | B2 |
6576007 | Dehdashtian et al. | Jun 2003 | B2 |
6579301 | Bales | Jun 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6613037 | Khosravi et al. | Sep 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6656214 | Fogarty et al. | Dec 2003 | B1 |
6656220 | Gomez et al. | Dec 2003 | B1 |
6663607 | Slaikeu et al. | Dec 2003 | B2 |
6663667 | Dehdashtian et al. | Dec 2003 | B2 |
6679300 | Sommer et al. | Jan 2004 | B1 |
6682546 | Amplatz | Jan 2004 | B2 |
6692486 | Jaafar et al. | Feb 2004 | B2 |
6695833 | Frantzen | Feb 2004 | B1 |
6699277 | Freidberg | Mar 2004 | B1 |
6729356 | Baker et al. | May 2004 | B1 |
6730119 | Smalling | May 2004 | B1 |
6733521 | Chobotov | May 2004 | B2 |
6761733 | Chobotov | Jul 2004 | B2 |
6773454 | Wholey et al. | Aug 2004 | B2 |
6776771 | Van Moorlegem et al. | Aug 2004 | B2 |
6827735 | Greenberg | Dec 2004 | B2 |
6843803 | Ryan et al. | Jan 2005 | B2 |
6878161 | Lenker | Apr 2005 | B2 |
6878164 | Kujawski | Apr 2005 | B2 |
6887268 | Butaric et al. | May 2005 | B2 |
6918926 | Letort | Jul 2005 | B2 |
6945989 | Betelia et al. | Sep 2005 | B1 |
6958051 | Hart et al. | Oct 2005 | B2 |
6960227 | Jones et al. | Nov 2005 | B2 |
6964667 | Shaolian et al. | Nov 2005 | B2 |
7001431 | Bao et al. | Feb 2006 | B2 |
7022100 | Aboul-Hosn et al. | Apr 2006 | B1 |
7105012 | Trout, III | Sep 2006 | B2 |
7112217 | Kugler | Sep 2006 | B1 |
7122052 | Greenhalgh | Oct 2006 | B2 |
7131991 | Zarins et al. | Nov 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7175651 | Kerr | Feb 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7326237 | Depalma et al. | Feb 2008 | B2 |
7435253 | Hartley et al. | Oct 2008 | B1 |
7530988 | Evans et al. | May 2009 | B2 |
7666220 | Evans et al. | Feb 2010 | B2 |
7682383 | Robin | Mar 2010 | B2 |
7708773 | Pinchuk et al. | May 2010 | B2 |
7790273 | Lee et al. | Sep 2010 | B2 |
7828838 | Bolduc et al. | Nov 2010 | B2 |
7872068 | Khosravi et al. | Jan 2011 | B2 |
7951448 | Lee et al. | May 2011 | B2 |
8044137 | Khosravi et al. | Oct 2011 | B2 |
8048145 | Evans et al. | Nov 2011 | B2 |
8182525 | Herbowy et al. | May 2012 | B2 |
8870941 | Evans | Oct 2014 | B2 |
20010020184 | Dehdashtian et al. | Sep 2001 | A1 |
20010027337 | Di Caprio | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010044655 | Patnaik et al. | Nov 2001 | A1 |
20020019665 | Dehdashtian et al. | Feb 2002 | A1 |
20020026217 | Baker et al. | Feb 2002 | A1 |
20020045848 | Jaafar et al. | Apr 2002 | A1 |
20020045931 | Sogard et al. | Apr 2002 | A1 |
20020052643 | Wholey et al. | May 2002 | A1 |
20020077594 | Chien et al. | Jun 2002 | A1 |
20020151953 | Chobotov | Oct 2002 | A1 |
20020151956 | Chobotov | Oct 2002 | A1 |
20020151958 | Chuter | Oct 2002 | A1 |
20020156518 | Tehrani | Oct 2002 | A1 |
20020165521 | Cioanta et al. | Nov 2002 | A1 |
20020169497 | Wholey et al. | Nov 2002 | A1 |
20020183629 | Fitz | Dec 2002 | A1 |
20030004560 | Chobotov | Jan 2003 | A1 |
20030009132 | Schwartz et al. | Jan 2003 | A1 |
20030014075 | Rosenbluth et al. | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030036745 | Khosravi et al. | Feb 2003 | A1 |
20030051735 | Pavcnik et al. | Mar 2003 | A1 |
20030074056 | Killion et al. | Apr 2003 | A1 |
20030078647 | Vallana et al. | Apr 2003 | A1 |
20030093145 | Lawrence-Brown et al. | May 2003 | A1 |
20030130720 | DePalma et al. | Jul 2003 | A1 |
20030130725 | DePalma et al. | Jul 2003 | A1 |
20030135269 | Swanstrom | Jul 2003 | A1 |
20030204242 | Zarins et al. | Oct 2003 | A1 |
20030204249 | Letort | Oct 2003 | A1 |
20030216802 | Chobotov et al. | Nov 2003 | A1 |
20030225446 | Hartley | Dec 2003 | A1 |
20040016997 | Ushio | Jan 2004 | A1 |
20040044358 | Khosravi et al. | Mar 2004 | A1 |
20040082989 | Cook et al. | Apr 2004 | A1 |
20040091543 | Bell et al. | May 2004 | A1 |
20040098096 | Eton | May 2004 | A1 |
20040116997 | Taylor et al. | Jun 2004 | A1 |
20040147811 | Diederich et al. | Jul 2004 | A1 |
20040153025 | Seifert et al. | Aug 2004 | A1 |
20040167607 | Frantzen | Aug 2004 | A1 |
20040193245 | Deem et al. | Sep 2004 | A1 |
20040204755 | Robin | Oct 2004 | A1 |
20040215172 | Chu et al. | Oct 2004 | A1 |
20040215316 | Smalling | Oct 2004 | A1 |
20040220522 | Briscoe et al. | Nov 2004 | A1 |
20040243057 | Vinten-Johansen et al. | Nov 2004 | A1 |
20050004660 | Rosenbluth et al. | Jan 2005 | A1 |
20050027238 | Fago et al. | Feb 2005 | A1 |
20050028484 | Littlewood | Feb 2005 | A1 |
20050065592 | Holzer | Mar 2005 | A1 |
20050090804 | Chobotov et al. | Apr 2005 | A1 |
20050096731 | Looi et al. | May 2005 | A1 |
20050215989 | Abboud et al. | Sep 2005 | A1 |
20050245891 | McCormick et al. | Nov 2005 | A1 |
20050251251 | Cribier | Nov 2005 | A1 |
20060015173 | Clifford et al. | Jan 2006 | A1 |
20060025853 | Evans et al. | Feb 2006 | A1 |
20060074481 | Vardi et al. | Apr 2006 | A1 |
20060135942 | Fernandes et al. | Jun 2006 | A1 |
20060142836 | Hartley et al. | Jun 2006 | A1 |
20060155369 | Edwin et al. | Jul 2006 | A1 |
20060161244 | Seguin | Jul 2006 | A1 |
20060184109 | Gobel | Aug 2006 | A1 |
20060206197 | Morsi | Sep 2006 | A1 |
20060222596 | Askari et al. | Oct 2006 | A1 |
20060265043 | Mandrusov et al. | Nov 2006 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20070032850 | Ruiz et al. | Feb 2007 | A1 |
20070043420 | Lostetter | Feb 2007 | A1 |
20070050008 | Kim et al. | Mar 2007 | A1 |
20070055355 | Kim et al. | Mar 2007 | A1 |
20070061005 | Kim et al. | Mar 2007 | A1 |
20070150041 | Evans et al. | Jun 2007 | A1 |
20070162109 | Davila et al. | Jul 2007 | A1 |
20070208416 | Burpee et al. | Sep 2007 | A1 |
20070276477 | Lee et al. | Nov 2007 | A1 |
20080039923 | Taylor et al. | Feb 2008 | A1 |
20080154368 | Justis et al. | Jun 2008 | A1 |
20080228259 | Chu | Sep 2008 | A1 |
20080294237 | Chu | Nov 2008 | A1 |
20090099649 | Chobotov et al. | Apr 2009 | A1 |
20090209855 | Drilling et al. | Aug 2009 | A1 |
20090216125 | Lenker | Aug 2009 | A1 |
20090318949 | Ganpath et al. | Dec 2009 | A1 |
20090319029 | Evans et al. | Dec 2009 | A1 |
20100004728 | Rao et al. | Jan 2010 | A1 |
20100036360 | Herbowy et al. | Feb 2010 | A1 |
20100106087 | Evans et al. | Apr 2010 | A1 |
20100217383 | Leonhardt et al. | Aug 2010 | A1 |
20120016456 | Herbowy et al. | Jan 2012 | A1 |
20120046684 | Evans et al. | Feb 2012 | A1 |
Number | Date | Country |
---|---|---|
4010975 | Oct 1991 | DE |
0679372 | Nov 1995 | EP |
1325717 | Jul 2003 | EP |
1903985 | Apr 2008 | EP |
2834199 | Jul 2003 | FR |
H04-322665 | Nov 1992 | JP |
2003-525692 | Sep 2003 | JP |
2004-537353 | Dec 2004 | JP |
2005-505380 | Feb 2005 | JP |
2005-532120 | Oct 2005 | JP |
2008-510502 | Apr 2008 | JP |
9717912 | May 1997 | WO |
9719653 | Jun 1997 | WO |
9853761 | Dec 1998 | WO |
9900073 | Jan 1999 | WO |
9944539 | Sep 1999 | WO |
0029060 | May 2000 | WO |
0051522 | Sep 2000 | WO |
0121108 | Mar 2001 | WO |
0166038 | Sep 2001 | WO |
02078569 | Oct 2002 | WO |
02083038 | Oct 2002 | WO |
02102282 | Dec 2002 | WO |
2003007785 | Jan 2003 | WO |
03032869 | Apr 2003 | WO |
03037222 | May 2003 | WO |
03053288 | Jul 2003 | WO |
2004004603 | Jan 2004 | WO |
2004026183 | Apr 2004 | WO |
2004037116 | May 2004 | WO |
2004045393 | Jun 2004 | WO |
2006012567 | Feb 2006 | WO |
2006116725 | Nov 2006 | WO |
2007008600 | Jan 2007 | WO |
2007142916 | Dec 2007 | WO |
Entry |
---|
Carmi et al., “Endovascular stent-graft adapted to the endoluminal environment: prototype of a new endoluminal approach,” J Endovasc Ther. Jun. 2002;9(3):380-381. |
Donayre et al., “Fillable Endovascular Aneurysm Repair,” Endovascular Today, pp. 64-66, Jan. 2009. |
Gilling-Smith, “Stent Graft Migration After Endovascular Aneurysm Repair,” presented at 25th International Charing Cross Symposium, Apr. 13, 2003 [Power Point Presentation and Transcript], 56 pages total. |
Journal of Endovascular Therapy; Apr. 2000; pp. 111, 114, 132-140; vol. 7′ No. 2; International Society of Endovascular Specialists; Phoenix, AZ. |
Patrick W. Serruys and Michael JB Kutryk; Handbook of Coronary Stents, Second Edition; 1998; pp. 45, 55, 78, 103, 112, 132, 158, 174, 185, 190, 207, 215, 230, 239; Martin Dunitz; UK. |
Shan-e-ali Haider et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device. Journal of Vascular Surgery. vol. 44, No. 4. 694-700. Oct. 2006. |
Susan M. Trocciola et al. The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: Characterization using a canine model. Journal of Vascular Surgery. Jan. 2006. p. 109-116. |
William Tanski, Mark Fillinger. Outcomes of original and low-permeability Gore Excluder endoprosthesis for endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery. Feb. 2007. p. 243-249. |
U.S. Appl. No. 60/855,889, filed Oct. 31, 2006; first named inventor: Steven L. Herbowy. |
U.S. Appl. No. 61/052,059, filed May 9, 2008; first named inventor: Gwendolyn A. Watanabe. |
Examination report of EP Application No. 06751879.5, dated Mar. 24, 2014. 5 pages. |
Number | Date | Country | |
---|---|---|---|
20150105848 A1 | Apr 2015 | US |
Number | Date | Country | |
---|---|---|---|
60589850 | Jul 2004 | US | |
60675158 | Apr 2005 | US | |
60736602 | Nov 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11413460 | Apr 2006 | US |
Child | 13285897 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13285897 | Oct 2011 | US |
Child | 14525019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11187471 | Jul 2005 | US |
Child | 11413460 | US |